Ironwood Pharmaceuticals is trading at $4.14, up 9.95%, after third-quarter revenue and diluted EPS topped estimates. - Revenue was $133.04 million versus $121.57 million estimated; diluted EPS was $0.36 versus $0.31. - The company raised 2026 revenue guidance to $485–$510 million and adjusted EBITDA outlook to above $350 million, citing LINZESS growth and improved commercial margins. - The earnings release is the clearest catalyst for the November 5 pre-market move.